论文信息 - Strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products - 字舞流文

Strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products

David R Jones | David R. Jones

[1] C. Coch,et al. Who is a ‘healthy subject’?—consensus results on pivotal eligibility criteria for clinical trials , 2017, European Journal of Clinical Pharmacology.

[2] Eric R. Ziegel,et al. Statistical Issues in Drug Development , 1997 .

[3] R. A. Bailey. Designs for dose–escalation trials with quantitative responses , 2009, Statistics in medicine.

[4] S. Senn,et al. Statistical issues in first‐in‐human studies on BIA 10‐2474: Neglected comparison of protocol against practice , 2017, Pharmaceutical statistics.

[5] R. A. Bailey,et al. Statistical issues in first‐in‐man studies , 2007 .